Shares of therapy developer Immuneering IMRX.O rise 2.6% to $5.01 premarket
Co reports Q4 adj. loss of 18 cents/shr vs analysts’ average estimate of 31 cents/shr – data compiled by LSEG
Co says cash runway expected to fund operations into 2029
IMRX says expanded pancreatic cancer cohort data on track for 1H 2026
Dosing in mid‑stage trial of cancer drugs atebimetinib and Libtayo in lung cancer expected in 2H 2026, per co
Shares up ~199% in 2025